Yes, administer alteplase to this patient with sinus bradycardia (HR 57 bpm) if primary PCI cannot be achieved within the recommended time window and there are no absolute contraindications to fibrinolysis.
Sinus bradycardia at 57 bpm is NOT a contraindication to fibrinolytic therapy for STEMI. The presence of bradycardia does not appear in either the absolute or relative contraindication lists for fibrinolysis 1.
Clinical Decision Framework
Step 1: Verify Indication for Reperfusion
- Symptoms present <12 hours with persistent ST-segment elevation 1, 2
- If primary PCI cannot be performed within 2 hours from first medical contact, fibrinolytic therapy is indicated 1
Step 2: Screen for Absolute Contraindications
The following are absolute contraindications that would preclude alteplase use 1:
- Any prior intracranial hemorrhage
- Known structural cerebral vascular lesion
- Known malignant intracranial neoplasm
- Ischemic stroke within 3 months (except acute ischemic stroke <4.5 hours)
- Suspected aortic dissection
- Active bleeding or bleeding diathesis
- Significant closed-head or facial trauma within 3 months
- Intracranial/intraspinal surgery within 2 months
- Severe uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg unresponsive to therapy)
Step 3: Assess Relative Contraindications
Relative contraindications require clinical judgment but do not absolutely prohibit treatment 1:
- History of chronic, severe, poorly controlled hypertension
- Significant hypertension on presentation (SBP >180 or DBP >110 mmHg)
- History of prior ischemic stroke >3 months
- Traumatic or prolonged CPR (>10 minutes)
- Major surgery (<3 weeks)
- Recent internal bleeding (2-4 weeks)
- Pregnancy
- Active peptic ulcer
- Oral anticoagulant therapy
Notably absent from both lists: bradycardia, heart rate parameters, or conduction abnormalities.
Recommended Alteplase Regimen
Use a fibrin-specific agent 2. The 2025 ACC/AHA guidelines provide specific dosing 1:
Alteplase (tPA) Dosing:
Adults ≥67 kg: 100 mg total
- 15 mg IV bolus
- 50 mg IV over 30 minutes
- 35 mg IV over next 60 minutes
Adults <67 kg:
- 15 mg IV bolus
- 0.75 mg/kg IV (max 50 mg) over 30 minutes
- 0.5 mg/kg IV (max 35 mg) over next 60 minutes
Essential Adjunctive Therapy
Administer concurrently 2:
- Aspirin: Oral or IV as soon as possible
- Clopidogrel: In addition to aspirin
- Anticoagulation: Enoxaparin IV followed by subcutaneous (preferred over unfractionated heparin) OR weight-adjusted UFH bolus followed by infusion
Post-Fibrinolysis Management
Immediate transfer to PCI-capable center is mandatory 2 for all patients after fibrinolysis, with specific timing based on clinical response:
- Emergency angiography/PCI: If heart failure or shock develops 2
- Rescue PCI immediately: If fibrinolysis fails (<50% ST-segment resolution at 60-90 minutes) or hemodynamic/electrical instability occurs 2
- Routine angiography/PCI: Between 2-24 hours after successful fibrinolysis 2
Critical Caveats Regarding Bradycardia
The bradycardia itself warrants attention but should not delay fibrinolysis:
- Monitor for progression: Sinus bradycardia at 57 bpm may be physiologic, medication-related, or represent inferior STEMI with vagal tone
- Have atropine ready: If symptomatic bradycardia develops (hypotension, altered mental status, chest pain, acute heart failure)
- Prepare for temporary pacing: If high-degree AV block develops during or after fibrinolysis
- Watch for reperfusion arrhythmias: Accelerated idioventricular rhythm or transient bradycardia may indicate successful reperfusion
Bleeding Risk Considerations
The most recent evidence shows alteplase carries a higher risk of intracranial hemorrhage compared to streptokinase 3, 4. However, this must be weighed against mortality benefit. The 2025 guidelines acknowledge this trade-off but maintain the Class I recommendation for fibrinolysis when PCI is not timely 1.
The accelerated alteplase regimen demonstrated survival advantage that persists at 1 year, with an estimated cost of $32,678 per year of life saved compared to streptokinase 4.
Time-Critical Nature
Initiate fibrinolysis as soon as possible after STEMI diagnosis, preferably in the pre-hospital setting 2. A 50% reduction in mortality is expected if treatment starts within the first hour 5. Benefit persists up to 12 hours from symptom onset 1, 4.
The presence of sinus bradycardia should prompt ECG monitoring with defibrillator capacity 2 but must not delay definitive reperfusion therapy when indicated and not contraindicated.